Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene effects on SARS-CoV-2 immunity after COVID-19 vaccination
2021-002476-39Phase 4Terminated
- Sponsor
- Dompé
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of raloxifene in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Dompé. Primary endpoint: SARS-CoV-2 specific neutralizing and binding antibody response. Started Aug 2021; status: terminated.
02
Drugs
raloxifene
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002476-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002476-39.